Activity Overview
The substantial increase in research in non–small-cell lung cancer (NSCLC) is paralleled with a significant growth of new clinical data and treatment options. This includes new-found techniques for treating patients who do not qualify for surgical resection, innovative methods for combination treatment, identification of the most effective therapies for initial management and maintenance of NSCLC, and the ability to use patient-specific characteristics to provide more personalized treatment. As the treatment armamentarium for NSCLC rapidly expands, oncology and oncology healthcare providers involved in the treatment of patients with NSCLC will need to learn the latest treatment options in order to bridge significant knowledge gaps that exist. This activity, which includes summaries of 4 posters presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, will discuss the clinical implications of this new research, providing an emphasis on tumor biology, ongoing clinical trials, and the latest treatment options for patients.
Goal
To provide oncologists and oncology healthcare providers with up-to-date information on the treatment and management of patients with NSCLC.
Intended Audience
This activity is designed for oncologists and healthcare providers who are actively involved in the management and treatment of NSCLC. No prerequisites required.
Learning Objectives
After reading this issue, participants should be able to:
- Evaluate new treatment options for NSCLC and the results of the latest clinical trials discussed at the ASCO 2009.
- Examine the role of combination therapy in the management of NSCLC.
- Identify the best medication(s) for initial management as well as maintenance treatment of NSCLC.
- Apply knowledge of patient-specific characteristics and/or tumor biomarkers to select appropriate therapy for individuals with NSCLC.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CE activity.
CE Information
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.5 Continuing Education Units (CEUs).
After reviewing this online activity, participants may receive a certificate of completion by filling out the course evaluation and successfully completing the CEU quiz.
Release date: September 30, 2009. Expiration date: September 30, 2011.
The estimated time to complete this activity: 30 minutes.
Activity Format
Web-based summaries of poster presentations from the 2009 ASCO Annual Meeting that discuss the clinical implications of this new research.
Full Disclosure Policy Affecting CE Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
David S. Ettinger, MD, FACP, FCCP (Chair)
Alex Grass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Dr Ettinger reports serving as a consultant for and receiving honoraria from AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Sanofi-Aventis.
Off-Label Product Discussion:
No speaker has indicated that their presentation will include information on off-label products.
Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
Internet CE Policy
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of The Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.
Summaries
Please read the following summaries and complete the post-test and evaluation in order to receive CEU credit for this activity.
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIB TRIAL (ATLAS) COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH B FOR FIRST-LINE TREATMENT OF LOCALLY ADVANCED, RECURRENT, OR METASTATIC NSCLC
SATURN: A DOUBLE-BLIND, RANDOMIZED, PHASE III STUDY OF MAINTENANCE ERLOTINIB VS PLACEBO FOLLOWING NONPROGRESSION WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH ADVANCED NSCLC
MAINTENANCE PEMETREXED PLUS BEST SUPPORTIVE CARE VS PLACEBO PLUS BEST SUPPORTIVE CARE: A RANDOMIZED PHASE III STUDY IN ADVANCED NSCLC
BIOMARKER ANALYSES FROM A PHASE III, RANDOMIZED, OPEN-LABEL, FIRST-LINE STUDY OF GEFITINIB VS CARBOPLATIN/PACLITAXEL IN CLINICALLY SELECTED PATIENTS WITH ADVANCED NSCLC IN ASIA (IPASS)
|
